VTGN
Vistagen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VTGN
Vistagen Therapeutics, Inc.
A late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders
343 Allerton Avenue, South San Francisco, California 94080
--
Vistagen Therapeutics, Inc., founded on May 26, 1998, is a clinical-stage biopharmaceutical company dedicated to the development of a new generation of therapies for anxiety, depression and certain other central nervous system (CNS) diseases for which the current treatment options are insufficient, resulting in a large unmet need in a large and growing global market, The product line includes three clinical-stage CNS product candidates, PH94B, PH10 and AV-101, each with a different mechanism of action, superior safety in all clinical studies to date, and therapeutic potential in a variety of CNS indications.
Earnings Call
Q2/2026
Estimate EPS-0.44
Actual EPS-0.54
Estimate Revenue145.80K
Actual Revenue258.00K
Vistagen's Q2 2026 Earnings Call: Contradictions Emerge on Top Line Timelines, Enrollment in PALISADE-4, and Recruitment Challenges
Nov 13,2025 07:43
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VTGN has released its 2026 Q2 earnings. EPS was reported at -0.54, versus the expected -0.44, missing expectations. The chart below visualizes how VTGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VTGN has released its 2026 Q2 earnings report, with revenue of 258.00K, reflecting a YoY change of 40.98%, and net profit of -19.42M, showing a YoY change of -49.81%. The Sankey diagram below clearly presents VTGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
